<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20150527163317+02'00'</creation_date><modification_date>D:20150527163317+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-01-178_h_dec_12.pdf</pdf_file></head><body><section><header>en  
   en</header><p>european 
 commission 
 brussels, 27.5.2015</p><p>c(2015) 3671 final</p></section><section><header>commission implementing decision of 27.5.2015 
 amending the marketing authorisation granted by decision c(2001)818 for &quot;targretin -
 bexarotene&quot;, a medicinal product for human use following an assessment of a periodic 
 safety update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission implementing decision of 27.5.2015 
 amending the marketing authorisation granted by decision c(2001)818 for &quot;targretin - 
 bexarotene&quot;, a medicinal product for human use following an assessment of a periodic 
 safety update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the council 
 of 31 march 2004 laying down community procedures for the authorisation and supervision of 
 medicinal products for human and veterinary use and establishing a european medicines 
 agency
 1, and in particular article 10 and 28 thereof, having regard to the opinion of the european medicines agency, formulated on 26 march 2015 
 by the committee for medicinal products for human use on the periodic safety update report for 
 this medicinal product, 
 whereas: 
 (1) 
 the placing on the market of the medicinal product &quot;targretin - bexarotene&quot; was 
 authorised by commission decision c(2001)818 of 29 march 2001. 
 (2) 
 the marketing authorisation holder submitted a periodic safety update report for this 
 medicinal product. this report was assessed by the pharmacovigilance risk assessment 
 committee as to whether the marketing authorisation(s) concerned should be maintained, 
 varied, suspended or withdrawn. 
 (3) 
 the scientific assessment performed by the committee for medicinal products for 
 human use, the conclusions of which are set out in annex iv to this decision, shows 
 that a decision should be taken amending the marketing authorisation for the medicinal 
 product concerned. 
 (4) 
 decision c(2001)818 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated.</p><p>
 1 oj l 136, 30.4.2004, p. 1.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>(5) for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the annexes 
 to decision c(2001)818 should therefore be replaced. 
 (6) 
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 decision c(2001)818 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to eisai limited, european knowledge centre, mosquito way, hatfield, hertfordshire al10 9sn, united kingdom. 
 done at brussels, 27.5.2015</p><p>for the commission</p><p>
 ladislav miko</p><p>
 acting director-general</p></section></body></xml>